US9074254 — Method of predicting a predisposition to QT prolongation
Method of Use · Assigned to Vanda Pharmaceuticals Inc · Expires 2031-12-28 · 6y remaining
What this patent protects
This patent protects a method for predicting a predisposition to QT prolongation and determining whether a compound, such as Fanapt, is capable of inducing QT prolongation.
USPTO Abstract
The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Drugs covered by this patent
- Fanapt (ILOPERIDONE) · Vanda Pharms Inc
- milsaperidone (Milsaperidone) · Vanda Pharmaceuticals
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1674 |
— | Fanapt |
U-1674 |
— | Fanapt |
U-1674 |
— | Fanapt |
U-1674 |
— | Fanapt |
U-1674 |
— | Fanapt |
U-4437 |
— | milsaperidone |
U-4437 |
— | milsaperidone |
U-4437 |
— | milsaperidone |
U-1674 |
— | Fanapt |
U-1674 |
— | Fanapt |
U-4436 |
— | milsaperidone |
U-4437 |
— | milsaperidone |
U-4437 |
— | milsaperidone |
U-4437 |
— | milsaperidone |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.